‘The Top 100 Manufacturers Of Molecular Diagnostics Worldwide’ is a useful reference tool for in-vitro diagnostic associations
-Biocartis Group NV – headquartered in Mechelen, Belgium, Biocartis Group NV is an innovative commercial stage molecular diagnostics company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis Group NV is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases, the fastest and largest growing segments of the $U.S. 5.0 billion MDx market. The Company employs 300 people and had revenue of $U.S. 16.7 million in 2015. Biocartis Group NV has been listed on Euronext Brussels (BCART) since April 2015 and is led by Rudi Pauwels, Chief Executive Officer.
-HiberGene Diagnostics – Founded in 2009, Hibergene Diagnostics is a Dublin, Ireland based, private Irish company that develops, manufactures and markets molecular diagnostic tests for human infectious diseases, using LAMP (Loop Mediated Isothermal Amplification) technology. In July, 2016, the Company launched its HG Group B Streptococcus (GBS) test. The GBS test, which has been developed for use in clinical settings, can be used to rapidly and accurately diagnose the presence of Group B Streptococcus in pregnant women and neonates. The test takes under an hour, is highly accurate and can be tested near patient, without the need for expensive laboratory equipment. The Company has a growing portfolio of tests in areas of unmet clinical need. Hibergene launched its HG Meningococcal test in November 2015 and plans to release further tests for C.difficile and Norovirus. Brendan Farrell is HiberGene Diagnostics’ Chief Executive Officer.